Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481730 | 0.84 | ALDH1A1 (0.65) | MAPK14ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL7221298 | 0.84 | MAPK14 (0.53) | MAPK14ALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL15750441 | 0.80 | LMNA (0.58) | MAPK14KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL15779140 | 0.79 | MAPK14 (0.57) | MAPK14KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL3375740 | 0.79 | MAPK14 (0.76) | MAPK14ALDH1A1NPC1RAB9ANOTUM | |
| Hydrochloric Acid SCHEMBL28362888 | 0.77 | MAPK14 (0.74) | MAPK14ALDH1A1NPC1RAB9ANOTUM | |
| SCHEMBL4497271 | 0.77 | ALDH1A1 (0.65) | MAPK14KEAP1NFE2L2ALDH1A1NPC1 | |
| SCHEMBL27677081 | 0.77 | CYP17A1 (0.41) | MAPK14KEAP1SMN1; SMN2POLBNR3C2 | |
| SCHEMBL2852336 | 0.76 | SMN1; SMN2 (0.74) | MAPK14KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL10340642 | 0.76 | MAPK14 (0.58) | MAPK14KEAP1NFE2L2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225335-A1 | Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| CN-101001626-A | Pyrazole derivatives for treating conditions mediated by activation of the adenosine A2b or A3 receptor | NOVARTIS AG (CH) | 2007-07-18 | — | — | CN | disclosed |
| EP-1799206-A2 | PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR | Novartis AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006015860-A2 | PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225335-A1 | Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor | ADORA3, ADORA2B, ADORA1 | MAPK14 3029/4885KEAP1 3872/4885NFE2L2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.